To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR
Revenue
2.58K+12.24% from last year
Operating profits
972.00+20% from last year
Net income
662.00+23.05% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012FY 2011FY 2010FY 2009FY 2008FY 2007FY 2006
Net worth14969.0013571.0012767.0011728.189294.617309.926957.155924.805357.394293.313495.362963.352500.602131.521797.481517.801241.38861.40535.41339.87
Fixed assets5442.004739.004722.004325.053703.872781.852087.771996.191559.191438.771308.891221.84908.72738.42589.93589.84589.86497.06381.38214.87
Debt2.00---0.3533.63105.6063.1135.7442.4726.6218.4233.0755.4423.0532.8552.6486.08153.96150.18
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012FY2011FY2010FY2009FY2008FY2007FY2006
Operating1653.001261.002459.001911.801946.931215.94954.30775.861150.371037.86826.33556.75479.97338.36326.55369.35301.15292.47181.9548.80
Investing -804.00-269.00-2707.00-2194.9275.13-83.47-685.40-478.30-1139.60-406.41-520.84-305.15-254.54-204.41-221.31-317.18-217.43-225.36-149.89-110.83
Financing -799.00-799.00-797.00-532.44-34.89-1091.42-245.94-314.162.38-631.12-302.95-248.50-230.76-131.11-104.16-47.60-82.31-65.09-34.5068.07

Financial ratios

Profitability ratiosinfo2
ROA13.02%
ROE15.35%
ROCE20.45%
EPS82.68%
Net profit margin23.41%
Operating profit margin35.3%
Dividend per share30%
Operational ratiosinfo2
Quick ratio3.4%
Current ratio4.84%
Interest coverage973%
Assets turnover0.56%
Debt to equity
Valuation ratiosinfo2
P/E ratio81.55%
P/B ratio11.94%
Dividend yield0.45%
EV/EBITDA
Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world. The company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
personal

Grow your wealth with more research recommendations

+91